Search clinical trials for: HIV-1 protease inhibitor GW640385 ritonavir RTV

Total 108812 results

ViiV Healthcare

Completed

GW640385 Plus Ritonavir And NRTIs For 48 Weeks In HIV-1 Infected Adults

HIV Infection | Infection, Human Immunodeficiency Virus I

United States
ViiV Healthcare

Terminated

A Dose Ranging Study Of GW640385 Boosted With Ritonavir (Rtv) In Comparison To A RTV-Boosted Protease Inhibitor (PI) In HIV-1 Infected PI-Experienced Adults

HIV-1 Infection | Infection, Human Immunodeficiency Virus I

United States, France, Germany, Canada, Italy, Australia, Belgium, Portugal, Puerto Rico, Romania, United Kingdom
Merck Sharp & Dohme LLC

Completed

A Study of Safety, Tolerability, and Immunogenicity of the MRKAd5 Gag/Pol/Nef Vaccine in Healthy Adults (V520-016)

HIV Infections | HIV-1
GlaxoSmithKline

Terminated

Open Label Study of 908/RTV in Combination With Other PIs for the Treatment of Multi PI-Experienced HIV Subjects

HIV-1

Australia, Belgium, Canada, France, Germany, Greece, Italy, Spain, United Kingdom
Wellness Wheel Medical Clinic
University of Saskatchewan; Saskatchewan Health Authority - Regina Area; CIHR...

Recruiting

Syphilis and HIV Point of Care Testing (POCT) in Saskatchewan (SHIVER)

HIV Infections | Syphilis

Canada
Cepheid

Completed

Clinical Evaluation of the Xpert® HIV-1 VL

Human Immunodeficiency Virus
Tibotec Pharmaceuticals, Ireland

Completed

A Phase 2 Study to Evaluate Pharmacokinetics, Safety and Efficacy of TMC114/Ritonavir (Rtv) in Human Immunodeficiency Virus (HIV)-1 Infected Children and Adolescents

HIV Infections | HIV-1

United States, France, Spain, Canada, South Africa, Argentina, Brazil, Romania
ViiV Healthcare

Terminated

Evaluation of the Safety, Tolerability and Pharmacokinetics (PK) of GSK3732394 First-Time-in-Human (FTIH) Study

HIV Infections

United States
National Institutes of Health Clinical Center (CC)

Completed

Nucleic Acid Amplification Testing (NAT) of Blood Donors for HCV and HIV

HIV Infection | Hepatitis C

United States
University of Aarhus
Aarhus University Hospital Skejby; Bandim Health Project; Abbott; Ministry of Health...

Completed

PI or NNRTI as First-line Treatment of HIV in West Africa - the PIONA Trial (PIONA)

HIV-1

Guinea-Bissau
Janssen-Cilag Ltd.

Completed

Early Access to Low-dose Ritonavir (TMC114/r) and Other Antiretrovirals (ARVs) for Treatment-naive or Early Treatment Experienced in HIV-1 Patients

HIV-1

Taiwan
Pfizer

Terminated

A Phase 2B Multicenter, Randomized, Comparative Trial Of UK-453,061 Versus Etravirine In Combination With Darunavir/Ritonavir And A Nucleos(t)Ide Reverse Transcriptase Inhibitor For The Treatment Of Antiretroviral Experienced HIV-1 Infected Subjects With Evidence Of NNRTI Resistant HIV-1

HIV-1

Spain, United Kingdom, Malaysia, United States, Portugal, Brazil, Germany, Italy, Poland, Puerto Rico, South Africa, Taiwan, Ukraine
ViiV Healthcare
Pfizer

Terminated

Comparative Trial Of Maraviroc Versus Emtricitabine/Tenofovir Both With Darunavir/Ritonavir In Antiretroviral-Naive Patients Infected With CCR5 Tropic HIV 1 (MODERN)

HIV-1

United States, Netherlands, Spain, Puerto Rico, Canada, Australia, Germany, Sweden, Poland, Portugal, Switzerland, France, Denmark, Italy, Belgium, United Kingdom, Hungary, Austria, Finland
Juan A. Arnaiz

Completed

Metabolic Effects of Atazanavir/Ritonavir Versus Darunavir/Ritonavir in Combination With Tenofovir/Emtricitabine in naïve HIV-1 Infected Patients

HIV-1

Spain
AIDS Clinical Trials Group
National Institute of Allergy and Infectious Diseases (NIAID)

Completed

Safety and Effectiveness of Raltegravir Plus Darunavir/Ritonavir in Treatment-Naive HIV-Infected Adults

HIV-1 Infections

United States
Gilead Sciences

Completed

Safety and Efficacy of Cobicistat-boosted Atazanavir Compared to Ritonavir-boosted Atazanavir in Combination With Emtricitabine/Tenofovir Disoproxil Fumarate in HIV-1 Infected, Antiretroviral Treatment-Naive Adults

HIV-1 Infection

United States
Tibotec Pharmaceuticals, Ireland
Tibotec Pharmaceutical Limited

Completed

A Study to Evaluate Antiviral Activity of Darunavir + Ritonavir in HIV-1 Infected Adolescents (DIONE)

HIV-1 Infection

France, United States, Spain, Ukraine, United Kingdom, Ireland
Janssen Sciences Ireland UC

Completed

TMC114IFD3001 - Study Providing Continued Access to Treatment With Darunavir (DRV)/Ritonavir(Rtv) in HIV1 Infected Adults, Adolescents and Children Aged 3 Years or Above and Coming From Previous Company Sponsored Studies With DRV

HIV-1 Infections

Costa Rica, Panama, South Africa, Ukraine, Malaysia, Brazil, Thailand, Guatemala
Janssen Sciences Ireland UC

Completed

TMC114-TiDP29-C232 - Study Providing Continued Access to Treatment With Darunavir (DRV)/Ritonavir (Rtv) for Children Coming From Any of the Three Ongoing Tibotec Sponsored Pediatric Studies With DRV

HIV-1 Infections

France, Ukraine, South Africa, United Kingdom, Argentina, Brazil, India, Spain
Gilead Sciences

Completed

Study to Evaluate Switching From Regimens Consisting of a Ritonavir-boosted Protease Inhibitor (PI) and Two Nucleoside Reverse Transcriptase Inhibitors (NRTIs) to a Fixed-dose Tablet Containing Emtricitabine/Rilpivirine/Tenofovir DF

HIV-1 Infection

United States, Spain, United Kingdom, Canada, Puerto Rico, France, Belgium, Italy, Germany, Austria
Castagna Antonella
Bristol-Myers Squibb; ViiV Healthcare

Completed

A Study of a Nucleoside Sparing Regimen in HIV-1 Infected Patients With Detectable Viremia (Dolatav)

HIV-1 Infection

Italy
IRCCS San Raffaele
Bristol-Myers Squibb

Completed

Efficacy of Atazanavir/Ritonavir Monotherapy as Maintenance in Patients With Viral Suppression

HIV-1 Infection

Italy
AIDS Clinical Trials Group
National Institute of Allergy and Infectious Diseases (NIAID)

Completed

Bone, Immunologic, and Virologic Effects of a Antiretroviral Regimen

HIV-1 Infection

United States, Puerto Rico
University of North Carolina, Chapel Hill
National Institute of Allergy and Infectious Diseases (NIAID)

Completed

More Than a Machine: Make Point-of-care HIV-1 Viral Load Testing Effective in Rural Uganda

HIV-1-infection

Uganda
Merck Sharp & Dohme LLC

Completed

Safety and Efficacy of Doravirine (MK-1439) in Participants With Human Immunodeficiency Virus 1 (HIV-1) (MK-1439-018) (DRIVE-FORWARD)

HIV-1
Gilead Sciences

Completed

Ritonavir-Boosted GS-9137 vs. Ritonavir-Boosted Protease Inhibitor(s) in Combination With Background ART.

HIV | Human Immunodeficiency Virus | HIV-1

United States, Puerto Rico
Hospital Universitari Vall d'Hebron Research Institute
University Hospital, Ghent; IrsiCaixa

Completed

HIV Reservoir Dynamics After Switching to Dolutegravir in Patients on a PI and 2 NRTI Based Regimen

HIV-1

Spain
MRC/UVRI and LSHTM Uganda Research Unit
Karolinska Institutet; Amsterdam Institute for Global Health and Development; University of Rwanda and other collaborators

Recruiting

East Africa Point of Care Viral Load Study (EAPoC-VL)

HIV | Viral Load | Point of Care Monitoring

Kenya, Uganda
Southern Illinois Healthcare Foundation
Janssen Scientific Affairs, LLC

Completed

A Retrospective Study to Evaluate the Safety and Efficacy of a Nucleoside-Sparing Regimen of Darunavir, Ritonavir, and Dolutegravir

HIV-1-infection
Centre Hospitalier Universitaire Saint Pierre
Gilead Sciences; University of Liege; Abbott; Pierre and Marie Curie University; University... and other collaborators

Completed

Nevirapine vs Ritonavir-boosted Lopinavir in ART Naive HIV-infected Adults in a Resource Limited Setting

HIV-1 Infection

Congo
The HIV Netherlands Australia Thailand Research...
Ministry of Education, Thailand

Completed

Lopinavir (LPV) Dose Reduction

HIV-1 Infections

Thailand
AbbVie

Completed

The Effectiveness of Dual Therapy (Lopinavir/Ritonavir + LamivudinE) in Treatment-Experienced HIV Infected Patients in the Russian Federation (SIMPLE)

HIV-1 Infection
Fundación Huésped
Ministry of Science and Technology,Argentine; National AIDS and STD programme... and other collaborators

Completed

Darunavir/Ritonavir + Lamivudine Versus Darunavir/Ritonavir +Emtricitabine/Tenofovir in Naïve HIV-1 Infected Subjects (ANDES)

HIV-1 Infection

Argentina
Kirby Institute

Completed

MARCH Central Nervous System Substudy

HIV-1 Infection

Argentina, Thailand, United Kingdom
Tibotec, Inc
Tibotec Therapeutics, a Division of Ortho Biotech Products, L.P., USA

Completed

A Study to Evaluate the Pharmacokinetic Profile (How the Body Absorbs, Distributes, Metabolizes and Eliminates a Drug) of TMC125 Plus Tenofovir/Emtricitabine Once Daily With or Without Darunavir/r Once Daily in Antiretroviral (ARV) Naive HIV-1 Patients (Patients Have Never Received ARV Treatment).

HIV-1 Infection
The HIV Netherlands Australia Thailand Research...
Chulalongkorn University; UMC St. Radboud, Nijmegen, The Netherlands

Completed

Lopinavir/Ritonavir (LPV/r) Tablet in HIV Infected Children

HIV-1 Infections

Thailand
Abbott

Completed

Clinical, Virological and Safety Outcomes of a Lopinavir/Ritonavir-Based Regimen in HIV-1 Infected Patients in Routine Clinical Use in China

HIV-1 Infections

China
AIDS Clinical Trials Group
National Institute of Allergy and Infectious Diseases (NIAID)

Completed

Study of Options for Second-Line Effective Combination Therapy (SELECT) (SELECT)

HIV-1 Infection

Peru, Kenya, Malawi, Brazil, South Africa, Zimbabwe, India, Thailand, Tanzania
Gilead Sciences

Completed

Study to Evaluate the Safety and Efficacy of Switching From Regimens Consisting of Boosted Atazanavir or Darunavir Plus Either Emtricitabine/Tenofovir or Abacavir/Lamivudine to Bictegravir/Emtricitabine/Tenofovir Alafenamide in Virologically Suppressed HIV-1 Infected Adults

HIV-1 Infection

Spain, United States, France, Germany, United Kingdom, Italy, Canada, Australia, Belgium, Puerto Rico, Dominican Republic
AIDS Clinical Trials Group
National Institute of Allergy and Infectious Diseases (NIAID); Merck Sharp... and other collaborators

Completed

A5288/MULTI-OCTAVE: Management Using Latest Technologies to Optimize Combination Therapy After Viral Failure (MULTI-OCTAVE)

HIV-1 Infection

Kenya, Brazil, South Africa, Uganda, Zimbabwe, India, Malawi, Haiti, Thailand, Peru
Centre de Recherches et d'Etude sur la Pathologie...
INSERM UMR S 1136

Completed

Study Evaluating the Efficacy of a Reduced Dose Atazanavir in HIV-1-infected Patients (ATALOW)

HIV-1 Infection

France
AIDS Clinical Trials Group
National Institute of Allergy and Infectious Diseases (NIAID)

Completed

Evaluating Pharmacokinetic Interactions With Vaginal Ring Contraceptives and ART

HIV-1 Infection

United States, Peru, Puerto Rico, Brazil, Botswana, Kenya, South Africa, Thailand
National Institute of Allergy and Infectious Diseases...

Completed

A Phase II Safety and Immunogenicity Trial of Live Recombinant Canarypox ALVAC-HIV vCP205 With or Without HIV-1 SF-2 RGP120 in HIV-1 Uninfected Adult Volunteers

HIV Infections

United States
Merck Sharp & Dohme LLC

Terminated

Investigation of V520 in a HIV Vaccine Dose Refinement Study (V520-027)(TERMINATED)

HIV Infections
Makerere University
University of Pittsburgh; University of Nebraska; University of Liverpool

Unknown

Darunavir and Rilpivirine Interactions With Levonorgestrel Implant (DRIVE-2)

Contraception | HIV-1-infection

Uganda
University of Washington
University of Nairobi

Completed

Patient Actor Training to Improve HIV Services for Adolescents in Kenya (SPEED)

HIV/AIDS

Kenya
Fundación Huésped
Pfizer

Unknown

Maraviroc (Celsentri) With Raltegravir and Darunavir/Ritonavir for the Treatment of Triple Class Failure in Adult HIV-1 Infected Patients (TERCETO)

AIDS | HIV-1 Adults Patients | Triple Class Failure

Argentina
National Cancer Institute (NCI)

Recruiting

Pomalidomide and Nivolumab in People With Virus-Associated Malignancies With or Without HIV

Kaposi Sarcoma | Viral Associated Malignancies | EBV/KSHV-associated Lymphomas

United States
ImmunityBio, Inc.

Active, not recruiting

QUILT-3.067: NANT Triple Negative Breast Cancer (TNBC) Vaccine: Molecularly Informed Integrated Immunotherapy in Subjects With TNBC Who Have Progressed on or After Standard-of-care Therapy.

Triple Negative Breast Cancer

United States
Ottawa Hospital Research Institute

Completed

Evaluating Optimal Timing of Endocrine Therapy and Radiation Therapy in Early-stage Breast Cancer (REaCT-RETT) (REaCT-RETT)

Early-stage Breast Cancer

Canada

3

Subscribe